Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses
US-2015374846-A1 · Dec 31, 2015 · US
US10400232B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10400232-B2 |
| Application number | US-201415026093-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 3, 2014 |
| Priority date | Oct 3, 2013 |
| Publication date | Sep 3, 2019 |
| Grant date | Sep 3, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Embodiments of the invention provide at least one polymer covalently conjugated to an esterase. The at least one polymer includes a plurality of oxime functional groups.
Opening claim text (preview).
We claim: 1. A composition comprising: at least one polymer covalently conjugated to an enzyme, the at least one polymer comprising a reactive functional group, wherein the reactive functional group reacts with an inhibitor attached to an active site of the enzyme. 2. The composition of claim 1 , wherein the enzyme comprises an esterase, and the reactive functional group comprises a plurality of oxime functional groups. 3. The composition of claim 2 , wherein the esterase is selected from the group consisting of acetylcholinesterase and butyrylcholinesterase. 4. The composition of claim 2 , wherein the esterase comprises chymotrypsin. 5. The composition of claim 2 , wherein the plurality of oxime functional groups comprises alkyne derivatives of 2-pyridine aldoxime. 6. The composition of claim 2 , wherein the plurality of oxime functional groups comprises an aldoxime. 7. The composition of claim 2 , wherein the plurality of oxime functional groups comprises a ketoxime. 8. The composition of claim 1 , wherein the reactive functional group reacts with the inhibitor attached to the active site of the enzyme, thus releasing the inhibitor from the active site and restoring activity to the active site of the enzyme. 9. The composition of claim 1 , wherein the at least one polymer comprises at least one environmentally responsive monomer. 10. The composition of claim 1 , wherein the at least one polymer is a copolymer comprising at least two different monomers, wherein at least one monomer is selected from the group consisting of aldoximes, ketoximes, muco-adhesion monomers, polyethylene glycol, bis-pyridinium oximes, N,N-dimethylacrylamide, N-isopropylacrylamide, (meth)acrylate, N,N-dimethylaminoethyl methacrylate, carboxyl acrylamide, 2-hydroxylethylmethacrylate, N-(2-hydroxypropyl)methacrylamide, quaternary ammonium monomers, sulfobetain methacrylate, oligo(ethylene glycol) methyl ether methacrylate, 2-PAM monomers, 4-PAM monomers, Clickable azide monomers, and combinations thereof. 11. A composition comprising: a bioconjugate comprising: an enzyme; and at least one polymer covalently conjugated to the enzyme, wherein the at least one polymer comprises a plurality of reactive functional groups, and at least one reactive functional group of the plurality of reactive functional groups is positioned to react, in use, with a functional group on an inhibitor attached to an active site of the enzyme. 12. The composition of claim 11 , wherein the enzyme comprises an esterase, and the at least one reactive functional group comprises a plurality of oxime functional groups. 13. The composition of claim 12 , wherein the at least one reactive functional group comprises an oxime functional group positioned to exert a nucleophilic attack on a phosphoryl functional group of the inhibitor when the phosphoryl functional group is attached to the active site of the esterase, said nucleophilic attack resulting in removal of the phosphoryl functional group from the active site and restoration of activity to the esterase. 14. The composition of claim 12 , wherein the at least one polymer of the bioconjugate comprises a flexibility sufficient to react, in use, with a phosphoryl functional group of the inhibitor attached to the active site of the esterase. 15. The composition of claim 12 , wherein the at least one polymer covalently conjugated to the esterase forms a long lived covalent conjugate that is maintained in the body for a time period ranging from more than about one day to more than about one week. 16. The composition of claim 12 , wherein the at least one polymer is a co-polymer comprising at least two different monomers, wherein at least one monomer comprises a member selected from the group consisting of aldoximes, ketoximes, muco-adhesion monomers, polyethylene glycol, bis-pyridinium oximes, N,N-dimethylacrylamide, N-isopropylacrylamide, (meth)acrylate, N,N-dimethylaminoethyl methacrylate, carboxyl acrylamide, 2-hydroxylethylmethacrylate, N-(2-hydroxypropyl)methacrylamide, quaternary ammonium monomers, sulfobetain methacrylate, oligo(ethylene glycol) methyl ether methacrylate, 2-PAM monomers, 4-PAM monomers, Clickable azide monomers, and combinations thereof.
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin · CPC title
Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4) · CPC title
Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates · CPC title
acting on ester bonds (3.1), e.g. lipases, ribonucleases · CPC title
Chymotrypsin (3.4.21.1) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.